David Aguilar1, Biykem Bozkurt, Kumudha Ramasubbu, Anita Deswal. 1. Winters Center for Heart Failure Research and Section of Cardiology, Department of Medicine, Baylor College of Medicine, 1709 Dryden Street-BCM 620, Suite 500, Box 13, Houston, Texas 77030, USA. daguilar@bcm.edu
Abstract
OBJECTIVES: This study was designed to examine the relationship between glycosylated hemoglobin (HbA1C) and adverse outcomes in diabetic patients with established heart failure (HF). BACKGROUND: Despite the common coexistence of diabetes and HF, previous studies examining the association between HbA1C and outcomes in this population have been limited and have reported discrepant results. METHODS: We assessed the association between increasing quintiles (Q1 to Q5) of HbA1C and risk of death or risk of HF hospitalization by conducting a retrospective study in a national cohort of 5,815 veterans with HF and diabetes treated in ambulatory clinics at Veterans Affairs medical centers. RESULTS: At 2 years of follow-up, death occurred in 25% of patients in Q1 (HbA1C < or =6.4%), 23% in Q2 (6.4% < HbA1c < or =7.1%), 17.7% in Q3 (7.1% < HbA1c < or =7.8%), 22.5% in Q4 (7.8% < HbA1c < or =9.0%), and 23.2% in Q5 (HbA1c >9.0%). After adjustment for potential confounders, the middle quintile (Q3) had reduced mortality when compared with the lowest quintile (risk-adjusted hazard ratio: 0.73, 95% confidence interval: 0.61 to 0.88, p = 0.001). Hospitalization rates for HF at 2 years increased with increasing quintiles of HbA1C (Q1: 13.3%, Q2: 13.1%, Q3: 15.5%, Q4: 16.4%, and Q5: 18.2%), but this association was not statistically significant when adjusted for potential confounders. CONCLUSIONS: The association between mortality and HbA1C in diabetic patients with HF appears U-shaped, with the lowest risk of death in those patients with modest glucose control (7.1% < HbA1C < or =7.8%). Future prospective studies are necessary to define optimal treatment goals in these patients.
OBJECTIVES: This study was designed to examine the relationship between glycosylated hemoglobin (HbA1C) and adverse outcomes in diabeticpatients with established heart failure (HF). BACKGROUND: Despite the common coexistence of diabetes and HF, previous studies examining the association between HbA1C and outcomes in this population have been limited and have reported discrepant results. METHODS: We assessed the association between increasing quintiles (Q1 to Q5) of HbA1C and risk of death or risk of HF hospitalization by conducting a retrospective study in a national cohort of 5,815 veterans with HF and diabetes treated in ambulatory clinics at Veterans Affairs medical centers. RESULTS: At 2 years of follow-up, death occurred in 25% of patients in Q1 (HbA1C < or =6.4%), 23% in Q2 (6.4% < HbA1c < or =7.1%), 17.7% in Q3 (7.1% < HbA1c < or =7.8%), 22.5% in Q4 (7.8% < HbA1c < or =9.0%), and 23.2% in Q5 (HbA1c >9.0%). After adjustment for potential confounders, the middle quintile (Q3) had reduced mortality when compared with the lowest quintile (risk-adjusted hazard ratio: 0.73, 95% confidence interval: 0.61 to 0.88, p = 0.001). Hospitalization rates for HF at 2 years increased with increasing quintiles of HbA1C (Q1: 13.3%, Q2: 13.1%, Q3: 15.5%, Q4: 16.4%, and Q5: 18.2%), but this association was not statistically significant when adjusted for potential confounders. CONCLUSIONS: The association between mortality and HbA1C in diabeticpatients with HF appears U-shaped, with the lowest risk of death in those patients with modest glucose control (7.1% < HbA1C < or =7.8%). Future prospective studies are necessary to define optimal treatment goals in these patients.
Authors: David E Goldstein; Randie R Little; Rodney A Lorenz; John I Malone; David Nathan; Charles M Peterson; David B Sacks Journal: Diabetes Care Date: 2004-07 Impact factor: 19.112
Authors: S B Williams; A B Goldfine; F K Timimi; H H Ting; M A Roddy; D C Simonson; M A Creager Journal: Circulation Date: 1998-05-05 Impact factor: 29.690
Authors: Kirkwood F Adams; Gregg C Fonarow; Charles L Emerman; Thierry H LeJemtel; Maria Rosa Costanzo; William T Abraham; Robert L Berkowitz; Marie Galvao; Darlene P Horton Journal: Am Heart J Date: 2005-02 Impact factor: 4.749
Authors: Alvaro M Murcia; Charles H Hennekens; Gervasio A Lamas; Manuel Jiménez-Navarro; Jean L Rouleau; Greg C Flaker; Steven Goldman; Hicham Skali; Eugene Braunwald; Marc A Pfeffer Journal: Arch Intern Med Date: 2004-11-08
Authors: Aslan T Turer; Craig R Malloy; Christopher B Newgard; Mihai V Podgoreanu Journal: Curr Opin Clin Nutr Metab Care Date: 2010-07 Impact factor: 4.294
Authors: Michael R MacDonald; Dean T Eurich; Sumit R Majumdar; James D Lewsey; Sai Bhagra; Pardeep S Jhund; Mark C Petrie; John J V McMurray; John R Petrie; Finlay A McAlister Journal: Diabetes Care Date: 2010-03-18 Impact factor: 17.152